Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „substrates“
Suchtreffer
Begriffe & Kennungen
Adcirca (previously Tadalafil Lilly) · 4.5 · 24 P-glycoprotein substrates (e.g. digoxin) Tadalafil (40 mg once per day) had no clinically significant effec
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · CYP1A2 substrates (e.g. theophylline) When tadalafil 10 mg was administered with theophylline (a non-selective
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · CYP1A2 substrates (e.g. theophylline) When tadalafil 10 mg was administered with theophylline (a non-selective
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · CYP2C9 substrates (e.g.R-warfarin) Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposur
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · CYP2C9 substrates (e.g.R-warfarin) Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposur
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · P-glycoprotein substrates (e.g. digoxin) Tadalafil (40 mg once per day) had no clinically significant effect o
Eintrag öffnenAdenuric · 4.5 · Desipramine/CYP2D6 substrates Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in he
Eintrag öffnenAdenuric · 4.5 · Desipramine/CYP2D6 substrates Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in he
Eintrag öffnenAdenuric · 4.5 · Rosiglitazone/CYP2C8 substrates Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in
Eintrag öffnenAdenuric · 4.5 · Rosiglitazone/CYP2C8 substrates Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in
Eintrag öffnenAdtralza · 4.5 · The effects of tralokinumab on the pharmacokinetics (PK) of CYP substrates, caffeine (CYP1A2), warfarin (CYP2C
Eintrag öffnenAkeega · 4.5 · CYP2C8 substrates Abiraterone is an inhibitor of CYP2C8. In a clinical study in healthy subjects, the AUC of p
Eintrag öffnenAkeega · 4.5 · Effects of niraparib or abiraterone acetate on other medicinal products CYP2D6 substrates Abiraterone is an in
Eintrag öffnenAkynzeo · 4.5 · Interaction with CYP3A4 substrates
Eintrag öffnenAkynzeo · 4.5 · Interaction with CYP3A4 substrates
Eintrag öffnenAkynzeo · 4.5 · Interaction with CYP3A4 substrates
Eintrag öffnenAkynzeo · 4.5 · Interaction with CYP3A4 substrates:
Eintrag öffnenAkynzeo · 4.5 · Netupitant/palonosetron capsules are unlikely to interact with medicinal products which are P-gp substrates. N
Eintrag öffnenAkynzeo · 4.5 · Netupitant/palonosetron sachets are unlikely to interact with medicinal products which are P-gp substrates. Ne
Eintrag öffnenAlecensa · 4.5 · Breast cancer resistance protein (BCRP) substrates In vitro, alectinib and M4 are inhibitors of the efflux tra
Eintrag öffnen